COT is an oncogene that can activate both the MAP kinase and JNK kinase pathways. COT activates IkappaB kinases and induces the nuclear production of NF-kappaB. C-terminal catalytic domain of KSR2 associates with COT and KSR2 can negatively regulates the kinase activity of COT in vitro. Co-transfection of KSR2 with COT in cells lead to reduced COT-mediated ERK activation and COT-induced IL8 production in a dose-dependent manner (1). Cot is one of the MAP kinase kinase kinases that regulates the ERK1/ERK2 pathway in response to IL-1. Blockage of expression of Cot results in failure of IL-1 to induce an increase in IL-8 and MIP-1betamRNA levels(2).
MAP3K8, EST, ESTF, TPL2, Tpl-2, c-COT, FLJ10486
1. Channavajhala, P L. et al: Identification of a novel human kinase supporter of Ras (hKSR-2) that functions as a negative regulator of Cot (Tpl2) signaling. J. Biol. Chem. 278: 47089-47097, 2003.
2. Rodríguez C. et al: TRAF6 and Src kinase activity regulates Cot activation by IL-1. Cell Signal. 2006 Sep;18(9):1376-85.
Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.
Sample Purity Data. For specific information on a given lot, see related technical data sheet.
Storage, Stability and Shipping:
Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
There are no related publications available for this product.
Cancer, ERK/MAPK Pathway, Inflammation, NfkB Pathway, Ser/Thr Kinases